semaglutide and optic neuropathy Anterior ischemic in patients treated with semaglutide: report of four cases with a possible association | BMC Ophthalmology Can Semaglutides (Ozempic) Cause Blindness?

Additionally, we have discovered five new adverse events (AE) which include abnormal sensation of pain, starvation ketosis acidosis, belching, follicular thyroid carcinoma, and mesenteric panniculitis

NASDAQ: LFMD and American Well Co

(In my opinion still the best modality) Key takeaway: Weight regain is common if therapy stops management must be sustained, multi-component, and patient-centered

Green coffee bean extract Green coffee beans are unroasted coffee beans

But then look at the GLP-1 data

Raise Your Brand Awareness Position your organization as a pioneer in next-generation GLP-1 therapeutics by ensuring your brand is visible to c-level executives, senior scientists, and strategic decision-makers dedicated to accelerating metabolic and neurodegenerative drug development Distinguish Yourself from the Crowd Differentiate your solutions and services in a fiercely competitive market by showcasing your breakthroughs to a focused audience actively seeking new technologies to gain a competitive edge beyond monotherapy Generate Commercial Opportunities Accelerate your business development objectives by directly engaging with decision-makers at major pharma and biotech companies by forging the crucial collaborations needed to secure your market position in the 2026 GLP-1 market Uncover the Next Market Trend Gain exclusive, front-line intelligence on the GLP-1 field, discovering emerging clinical and commercial data and strategies for high-value indication expansion into neurological disorders, cardiorenal protection and women's health Brush Shoulders with Industry Experts Directly network with key opinion leaders, speakers, and leading innovators, including representatives from major pharma, innovative biotechs ensuring you are part of the conversation defining the future of GLP-1 drug development Key Services & Solutions Our attendees from GLP-1 biopharma are looking for service and solution providers with capabilities in the below areas but not limited to: Preclinical CROs With particular interest in models of obesity including, muscle models, to validate trial findings in preclinical models Clinical CROs Contract research organisations to assist with the planning and coordinating sites for clinical trials Diagnostics & Imaging Imaging (MRIs etc) for obesity, cardiovascular, renal, metabolic as a biomarker and endpoint RWE & HEOR Real world evidence, health economics outcomes research data companies to collect and analyse the real-world data for trials Hear What Our Past Sponsors Have to Say The sessions were amazing and there was a very good opportunity to discuss and meet with all of the meeting participants Senior Director, Antaros Medical AB The quality of the program and participants, not to mention the number of opportunities to connect Director, Scientific & Business Development, Cardiomedex Audience Composition 2026 Attending Companies Included Get in Touch Take advantage of our bespoke sponsorship opportunities to achieve your commercial goals